Blueprint Medicines (Nasdaq: BPMC) has announced positive top-line results from the registrational Part 2 of the PIONEER clinical trial of Ayvakit (avapritinib).
The study is examining the impact of Ayvakit, a kinase inhibitor, on people with non-advanced systemic mastocytosis (SM).
Blueprint said that top-line data show clinically-meaningful and highly-significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms as well as objective measures of mast cell burden.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze